

WARNING: CHOLESTEROL EFFLUX MALFUNCTION



SEE THE JOURNEY OF CHOLESTEROL
SCAN THE QR CODE TO VISIT
www.DiscoverCholesterolEfflux.com

FIND OUT MORE ABOUT THE ROLE OF CHOLESTEROL EFFLUX
IN REMOVING EXCESS CHOLESTEROL FROM ARTERIAL PLAQUE

VISIT CSL BEHRING AT BOOTH #1211 DURING AHA 2023

PAID ADVERTISEMENT

CSL Behring is pleased to support the American Heart Association 2023 Learning Studio:

Spotlight on Cholesterol Efflux: Uncovering Potential Cardioprotective Benefits in the 90-Day High-Risk Period Post AMI

Saturday, November 11, 2023 | 12:30 PM - 1:15 PM EST
Learning Studio I



Scan here to access the symposium information

Faculty



Dr. Deepak L. Bhatt (Chair)
Mount Sinai Heart, USA



Dr. Peter Libby, MD
Brigham and Women's Hospital
and Harvard Medical School, USA

In this thought-provoking symposium, our expert faculty will outline the HDL hypothesis and how it is evolving. We will highlight the association between cholesterol efflux capacity and cardiovascular outcomes and discuss how this has changed our outlook on the original HDL hypothesis. Finally, we will review the residual risk of recurrent CV events following MI and ask why cholesterol efflux capacity is an important mechanism to consider when seeking to further reduce this risk.

Agenda

TIME (EST)	SESSION	SPEAKER(S)
12:30–12:33 PM	Welcome and Introductions	Dr. Deepak L. Bhatt
12:33–12:43 PM	Cholesterol Efflux: Reshaping our Understanding of the HDL Hypothesis: Understand the role of ApoA-I in reverse cholesterol transport and the potential for cholesterol efflux to improve CV outcomes	Dr. Peter Libby
12:43–12:48 PM	Faculty Discussion	
12:48–12:58 PM	Why do we Need to Explore Additional Treatment Options for Patients Post AMI? How the 90-day high-risk period post AMI underpins the need to further improve CV outcomes beyond our current SOC	Dr. Deepak L. Bhatt
12:58–1:03 PM	Faculty Discussion	
1:03–1:13 PM	Audience Q&A	
1:13–1:15 PM	Summary and Close	Dr. Deepak L. Bhatt

This event is not part of the official Scientific Sessions Conference 2023 as planned by the AHA Committee on Scientific Sessions Programming.

AMI, acute myocardial infarction; ApoA-I, apolipoprotein A-I; CV, cardiovascular; HDL, high-density lipoprotein; MI, myocardial infarction; SOC, standard of care. The learning studio and medical exhibition booth have been organized and funded by CSL Behring and are intended exclusively for healthcare professionals.

©2023 CSL Behring LLC 1020 First Avenue, PO Box 61501, King of Prussia, PA 19406-0901, USA
www.CSLBehring.com | <https://www.discovercholesterolefflux.com/> | CMD-MY-0112 | September 2023

CSL Behring